Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 2
1987 2
1988 2
1990 3
1991 1
1992 5
1993 3
1994 2
1995 2
1996 4
1997 3
1998 1
1999 4
2000 8
2001 3
2002 2
2003 5
2004 5
2005 4
2006 4
2007 5
2008 4
2009 7
2010 7
2011 5
2012 3
2013 4
2014 5
2015 5
2016 8
2017 9
2018 8
2019 1
2020 3
2021 3
2022 5
2023 6
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

145 results

Results by year

Filters applied: . Clear all
Page 1
Abemaciclib Is Effective in Palbociclib-Resistant Hormone Receptor-Positive Metastatic Breast Cancers.
Navarro-Yepes J, Kettner NM, Rao X, Bishop CS, Bui TN, Wingate HF, Singareeka Raghavendra A, Wang Y, Wang J, Sahin AA, Meric-Bernstam F, Hunt KK, Damodaran S, Tripathy D, Keyomarsi K. Navarro-Yepes J, et al. Among authors: keyomarsi k. Cancer Res. 2023 Oct 2;83(19):3264-3283. doi: 10.1158/0008-5472.CAN-23-0705. Cancer Res. 2023. PMID: 37384539 Free PMC article.
Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers.
DiPeri TP, Evans KW, Raso MG, Zhao M, Rizvi YQ, Zheng X, Wang B, Kirby BP, Kong K, Kahle M, Yap TA, Dumbrava EE, Ajani JA, Fu S, Keyomarsi K, Meric-Bernstam F. DiPeri TP, et al. Among authors: keyomarsi k. Clin Cancer Res. 2023 Nov 1;29(21):4385-4398. doi: 10.1158/1078-0432.CCR-23-0103. Clin Cancer Res. 2023. PMID: 37279095 Free PMC article.
Cell cycle arrest induces lipid droplet formation and confers ferroptosis resistance.
Lee H, Horbath A, Kondiparthi L, Meena JK, Lei G, Dasgupta S, Liu X, Zhuang L, Koppula P, Li M, Mahmud I, Wei B, Lorenzi PL, Keyomarsi K, Poyurovsky MV, Olszewski K, Gan B. Lee H, et al. Among authors: keyomarsi k. Nat Commun. 2024 Jan 2;15(1):79. doi: 10.1038/s41467-023-44412-7. Nat Commun. 2024. PMID: 38167301 Free PMC article.
Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification.
Fu S, Yao S, Yuan Y, Previs RA, Elias AD, Carvajal RD, George TJ, Yuan Y, Yu L, Westin SN, Xing Y, Dumbrava EE, Karp DD, Piha-Paul SA, Tsimberidou AM, Ahnert JR, Takebe N, Lu K, Keyomarsi K, Meric-Bernstam F. Fu S, et al. Among authors: keyomarsi k. J Clin Oncol. 2023 Mar 20;41(9):1725-1734. doi: 10.1200/JCO.22.00830. Epub 2022 Dec 5. J Clin Oncol. 2023. PMID: 36469840 Free PMC article. Clinical Trial.
Evaluation of Alisertib Alone or Combined With Fulvestrant in Patients With Endocrine-Resistant Advanced Breast Cancer: The Phase 2 TBCRC041 Randomized Clinical Trial.
Haddad TC, Suman VJ, D'Assoro AB, Carter JM, Giridhar KV, McMenomy BP, Santo K, Mayer EL, Karuturi MS, Morikawa A, Marcom PK, Isaacs CJ, Oh SY, Clark AS, Mayer IA, Keyomarsi K, Hobday TJ, Peethambaram PP, O'Sullivan CC, Leon-Ferre RA, Liu MC, Ingle JN, Goetz MP. Haddad TC, et al. Among authors: keyomarsi k. JAMA Oncol. 2023 Jun 1;9(6):815-824. doi: 10.1001/jamaoncol.2022.7949. JAMA Oncol. 2023. PMID: 36892847 Free PMC article. Clinical Trial.
Leveraging MYC as a therapeutic treatment option for TNBC.
Carey JPW, Keyomarsi K. Carey JPW, et al. Among authors: keyomarsi k. Oncoscience. 2018 Jun 24;5(5-6):137-139. doi: 10.18632/oncoscience.424. eCollection 2018 May. Oncoscience. 2018. PMID: 30035166 Free PMC article. No abstract available.
145 results